Clinical Trial Update: PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

View source ↗

Summary

PROVIDENCE is a prospective non-interventional study evaluating patient-reported outcomes and real-world data in patients with HER2-expressing unresectable or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: AstraZeneca | Conditions: Breast Neoplasms, Breast Cancer | Status: RECRUITING